5 stories mentioning ICLRUpdated just now
Every FINWIRES story that references ICLR, newest first.
ICON (ICLR) has an average rating of overweight and mean price target of $175, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $150 from $120, representing 14.3x our 2026 EPS estimate, below peers and ICLR's 16.1x forward P/E average over the past five years. Our 2026 EPS view is $10.50 (down from $12.66), and we start our 2027 estimate at $11.96. While we think ICLR's accounting issues have been resolved, the company continues to operate within a challenging environment for life sciences tools & services firms, and the sub-industry trades at a wide discount to recent historical valuations. We expect 2026 will be a trough year in terms of sales, margins, and earnings before growth improves in 2027. ICLR's stricter cancellation policy resulted in a one-time $3.9 billion downward adjustment to the backlog ($21.8B as of year-end 2025). However, management noted that over 75% of this adjustment related to awards from 2023 or earlier. ICLR does not pay a shareholder dividend, but the company repurchased $750M of stock during 2025 at an average price of $167 per share.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ICON reported challenging Q4 results with sales of $2.11B (+2.5% Y/Y, $130M above consensus) but adjusted EPS of $2.52 fell $0.59 short of estimates and declined 26.5%. Full-year 2025 sales of $8.25B rose just 0.8%, while adjusted EBITDA margin contracted meaningfully to 18.6% (-180 bps), reflecting industry headwinds including elevated cancellations and pricing pressure. A bright spot was strong bookings momentum with $3.2B in Q4 gross wins supporting a robust 1.36 book-to-bill ratio, while the completed accounting investigation resulted in minimal revenue restatements of 0.8%-1.1% for 2023-2024 with no operational impact. For 2026, ICLR guided to revenue of $7.85B-$8.15B and EPS of $10.00-$11.00, representing declines of about 3% and 16%, respectively, at the midpoint. The guidance reflects continued near-term margin pressure and operational challenges, in our view, though management expressed confidence in large pharma spending recovery and improving biotech funding conditions.
Icon (ICLR) is poised to benefit from increasing clinical trial activity with its strong relationships with large pharmaceutical firms and exposure to growing areas such as oncology and cardiometabolic therapies, RBC Capital Markets said in a Monday note that resumed coverage of the company.RBC's research suggests that biopharmaceutical financing stabilization and accelerating mergers and acquisitions, among other factors, point to strong momentum in the use of contract research organizations such as Icon.With more than 40% of its revenue from top 10 customers, Icon's exposure to large pharmaceutical firms should protect it from a wave of project cancellations affecting competitors, RBC analysts said.The company should be positioned to benefit as its key partners are facing loss-of-exclusivity risks while having substantial capital to invest in acquiring new assets and building new pipelines, the analysts said.Icon's accounting review has been completed with a favorable conclusion, but the analysts said they need additional disclosures on key performance indicators, as well as restated financials and reissued guidance, before they consider taking a more constructive view on the company.RBC resumed coverage of the company with a Sector Perform rating and a price target of $123.Price: $116.33, Change: $-0.05, Percent Change: -0.04%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ICLR shares rallied following completion of the accounting investigation, with revenue overstatement below the previously expected 2% level for 2023-2024 and even lower for 2025 through Q3. The company will restate financial results for all impacted periods, with an annual report expected before the end of Q2. We think today's rally makes sense given the removal of a long-standing overhang and avoidance of worst-case scenarios, including client damages, fraud, or over 2% revenue misstatement for 2023-2024. Management commentary suggests a potential improvement in pharma/biotech funding environment and project cancellation trends that have posed recent headwinds. While we expect ICLR will gradually regain investor confidence, we think the operational environment remains challenging for the company and peers in the life sciences tools & services sub-industry. We believe visibility remains low given the lack of recent financial guidance and await updated financials for more evidence of the suggested improvements.
